Opus Genetics (IRD): Chief Operating Officer sold ~$17K
Joseph K Schachle, Chief Operating Officer at Opus Genetics, sold ~$17K of Opus Genetics shares.
- ~$17K
- Approx. value · 4,767 sh @ $3.57
- 287K
- Holds after · shares reported
- Traded
- Oct 23, 2026
- Filed
- Oct 27, 2026
The story around this disclosure
Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.
- Sep 30, 2026InsiderDirector sold ~$2.76M of IRD shares in the open market
- Oct 19, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“Opus Genetics, Inc. (the “Company”) and Ashwath Jayagopal have agreed that Dr. Jayagopal will transition from his role as the Company’s Chief Scientific and Development Officer, effective as of October 19, 2026 (the “Separation Date”).”
- Oct 23, 2026 · this disclosureInsiderOfficer sold ~$17K of IRD shares in the open market
What came next
- Oct 23, 2026Insider · 3 peopleInsiders: 4 sales (~$201K)
- Oct 27, 20265% stakeBlackRock, Inc. reported a passive stake (13G) of 6.1%
- Nov 3, 2026InsiderCEO sold ~$110K of IRD shares in the open market
- Nov 10, 2026Company filing · Form 8-K · ResultsReported its results
- Nov 12, 20265% stakeAdage Capital Management, L.P. reported a passive stake (13G) of 2.7%
- Nov 16, 20265% stakeCaligan Partners LP reported a passive stake (13G) of 6.2%
- Nov 16, 20265% stakeBoxer Capital Management, LLC reported a passive stake (13G) of 5.4%
- Nov 16, 20265% stakePerceptive Advisors LLC reported a passive stake (13G) of 10.0%
- Nov 16, 20265% stakeBALYASNY ASSET MANAGEMENT L.P. reported a passive stake (13G) of 7.4%
- Nov 16, 20265% stakeCormorant Asset Management, LP reported a passive stake (13G) of 6.6%
How to read SEC Form 4
Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.
Full guide: What is an SEC Form 4?
What else is on file for Opus Genetics
For Opus Genetics, OQRO holds 11 insider filings (SEC Form 4 or Form 144) and 3 fund holdings reports (13F) dated in the last 90 days.
These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its IRD page.
How this filing works
Explore the data
Common questions
Which Opus Genetics (IRD) insider traded, and how much?
Joseph K Schachle, Chief Operating Officer at Opus Genetics, sold ~$17K of Opus Genetics shares. 4,767 shares at $3.57.
When did it happen, and when was it made public?
Traded: Oct 23, 2026. Filed: Oct 27, 2026. That is 4 days between the two dates.
Is the dollar amount exact?
It is the number of shares multiplied by the price the insider reported on the form. A grant, a gift or an option exercise has no market price, so those show shares only.
Where does this information come from?
From the SEC Form 4, a public record. The link to the official record is on this page, and OQRO copies its figures without changing them.
What else has been disclosed about Opus Genetics recently?
For Opus Genetics, OQRO holds 11 insider filings (SEC Form 4 or Form 144) and 3 fund holdings reports (13F) dated in the last 90 days. They are listed on the IRD page.
Does this mean IRD stock is a buy or a sell?
No. This page describes one public filing. A filing does not say why someone traded and is not a forecast, so OQRO gives no recommendation.
Is OQRO free?
Yes. Every page of OQRO is free with an account, which takes a minute with Google and needs no card. Only the AI assistant is paid.
Other disclosures at Opus Genetics
- SEC Schedule 13GNov 16, 2026
- SEC Schedule 13GNov 16, 2026
- SEC Schedule 13GNov 12, 2026
- SEC Form 4Nov 5, 2026
- SEC Form 144Nov 3, 2026
- SEC Form 4Oct 27, 2026
Everything OQRO holds on this company is on its IRD page.
This is one filing. OQRO holds the rest
Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.
OQRO is free for everyone. No card, no trial
OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data
